An observational study of the discrediting of COX-2 NSAIDs in Australia: Vioxx or class effect?

BMC Public Health

Table 2 Population at risk (N), incident cases, incidence rate and IRR, by medicine and rofecoxib user status, for ALSWH Older cohort

	Continuous Users			Non-Continuous Users			IRR (95% CI)
Medicine	N^a	Cases	Incidence rate (per 100,000 person days)	N^a	Cases	Incidence rate (per 100,000 person days)
COX-2s Overall	163	130	272.2	320	146	58.8	4.6 (3.6,5.9)
Celecoxib	163	59	44.9	320	54	16.7	2.7 (1.8,4)
Lumiracoxib	163	12	6.7	320	17	4.7	1.4 (0.6,3.2)
Meloxicam	163	98	111.3	320	100	34.8	3.2 (2.4,4.3)
ns-NSAIDs Overall	137	56	47.9	274	101	40.7	1.2 (0.8,1.6)
Diclofenac	137	14	9.6	274	24	8.0	1.2 (0.6,2.4)
Ibuprofen	137	10	6.6	274	15	4.9	1.4 (0.5,3.2)
Naproxen	137	10	6.6	274	8	2.6	2.6 (0.9,7.5)
Piroxicam	137	43	33.2	274	95	37.9	0.9 (0.6,1.3)
Acetylsalicylic acid	137	4	2.6	274	3	1.0	2.7 (0.5,18.4)
Other ns-NSAIDs	137	5	3.2	274	9	2.9	1.1 (0.3,3.7)
Opioids Overall	143	45	32.5	321	86	26.7	1.2 (0.8,1.8)
Buprenorphine	143	5	3.0	321	12	3.2	0.9 (0.3,2.9)
Morphine	143	5	3.0	321	19	5.1	0.6 (0.2,1.6)
Oxycodone	143	15	9.3	321	33	9.2	1 (0.5,1.9)
Tramadol	143	36	25.5	321	52	15.5	1.7 (1,2.6)
Other Opioids	143	2	1.2	321	4	1.1	1.1 (0.1,7.9)
Paracetamol Overall	71	56	138.0	171	96	76.6	1.8 (1.3,2.5)
Paracetamol and combinations excl. psycholeptics	71	56	138.0	171	96	76.4	1.8 (1.3,2.5)
Codeine, combinations excl. psycholeptics	71	3	3.7	171	6	3.1	1.2 (0.2,5.6)

^a Includes only women not dispensed these medicines in the 12 months prior to rofecoxib withdrawal

ISSN: 1471-2458